Mobilan (M-VM3) / Statera BioPharma - LARVOL DELTA

Flagellins as Vaccine Adjuvants and Cancer Immunotherapy: Recent Advances and Future Prospects. (PubMed, Immunology) - "Mobilan, a recombinant non-replicating adenovirus vector expressing Salmonella flagellin, is currently in a phase Ib clinical trial for prostate cancer. Overall, bacterial flagellin treatments are generally safe, well-tolerated, and associated with minimal side effects, making them a promising option for managing infectious diseases and cancers."

Journal • Review • Cholera • Colorectal Cancer • Dengue Fever • Genito-urinary Cancer • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Influenza • Lymphoma • Malaria • Melanoma • Mucositis • Oncology • Prostate Cancer • Respiratory Diseases • Solid Tumor • CXCL8 • IL12A • IL1B • IL6 • TNFA

Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels. (PubMed, J Proteome Res) - "For genotypes PI*M1VM3 and PI*M1AM3, a significant higher amount of M3 was observed compared to the M1-subtypes (M1V/M3, 1.00:1.84 ± 0.35, n = 8; M1A/M3, 1.00:1.61 ± 0.33, n = 5). We argue that these observations are important and should be considered when analyzing serum A1AT levels before proposing A1AT as a putative serum biomarker."

Journal • Alpha-1 Antitrypsin Deficiency • Hepatology • Pulmonary Disease • Respiratory Diseases • SERPINA1

Synthesis of 8,12-Dibromocorrole and Its Transformation to Antiaromatic 8,10-Fused Iminoisocorrole with a Polarized Resonance Contribution. (PubMed, Chem Asian J) - "8,12-Dibromo-5,15-bis(pentafluorophenyl)corrole and its Ag(III) complex were prepared via intramolecular oxidative coupling of a 8,12-dibromobilane precursor...Thus, 2-aminophenyl group was coupled at one of the β -positions, and subsequent demetalation followed by oxidation with MnO 2 afforded 8,10-fused iminoisocorrole in good yields. The iminoisocorrole exhibited weak antiaromaticity due to the C(+)-N(-) polarized resonance contribution as evidenced by 1 H NMR spectrum, UV/vis absorption spectra, cyclic voltammetry, and theoretical calculations."

Journal

First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. (PubMed, Oncotarget) - "Therefore, Mobilan is well-tolerated and induces the expected pharmacodynamic response in humans. These results support further clinical development of Mobilan as a novel immunotherapy for prostate cancer."

Clinical • IO Biomarker • Journal • P1 data • PK/PD data • Genito-urinary Cancer • Immunology • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer • IL6